Nerviano, 5 May 2022
NMS Group SpA today announced that its CEO, Hugues Dolgos, has accepted the resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl, effective 31 May 2022. Hugues Dolgos will act as interim CEO for both companies. A search for a permanent CEO will begin shortly.
“I look forward to working even closely with our colleagues from Accelera and NerPharMa to complete our on-going transformation plan together and achieve our strategic goals, to create more values to our Board and clients and eventually benefit patients globally,” said Dr. Dolgos.
Mr. David Wong, Chairman of NMS Group SpA stated, “The Board is excited to have Hugues expand his responsibilities building on his amazing progress in the past few months. We are sure that Hugues will lead the group with his integral knowledge of all aspects of the business and his strong relationships throughout the industry to bring more opportunities to the companies. I wish him all the best in his future endeavors and thank him on behalf of the entire Board.”
Mr. Colombo stated, “I want to thank everyone that worked side by side with me and made Accelera and NerPharMa two leading CRO and CDMO today. It has been a great honor to work with our investors, Board and brilliant team over the past 5 years. I realize that all journeys must ultimately come to an end and want to wish Hugues and the entire team success as they continue to grow the business.”